Authors' objectives: We have systematically collected and reviewed the evidence for clinical effectiveness and general safety issues for disease modifying treatments for relapsing remitting multiple sclerosis, synthesised evidence from randomised controlled trials and non-randomised registry-based studies using network meta-regression, and carefully interpreted the findings.
Multiple Sclerosis; Relapsing-Remitting; A; Alemtuzumab;; Cladribine; Dimethyl Fumarate;; Fingolimod Hydrochloride;; Glatiramer Acetate; Natalizumab;; Ocrelizumab;; Rituximab; Teriflunomide; Interferon-beta; Off-Label Use; Drug-Related Side Effects and Adverse Reactions; Network Meta-Analysis; Cost-Benefit Analysis; Systematic Review as Topic;; Technology Assessment
10.5
